BR0016669A - Composto, e, composição farmacêutica - Google Patents

Composto, e, composição farmacêutica

Info

Publication number
BR0016669A
BR0016669A BR0016669-3A BR0016669A BR0016669A BR 0016669 A BR0016669 A BR 0016669A BR 0016669 A BR0016669 A BR 0016669A BR 0016669 A BR0016669 A BR 0016669A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
compound
farnesylation
compounds
methods
Prior art date
Application number
BR0016669-3A
Other languages
English (en)
Inventor
Francis Thomas Boyle
James Michael Wardleworth
Zbigniew Matusiak
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR0016669A publication Critical patent/BR0016669A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"COMPOSTO, E, COMPOSIçãO FARMACêUTICA". Esta invenção diz respeito a compostos de fórmula (I) que inibem a farnesilação de produtos de gene através da inibição da enzima farnesil-proteína transferase (FPTase). A invenção também diz respeito a métodos de fabricação dos compostos, composições farmacêuticas e métodos de tratar doenças, especialmente câncer, que são mediadas através da farnesilação.
BR0016669-3A 1999-12-22 2000-12-18 Composto, e, composição farmacêutica BR0016669A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9930318.2A GB9930318D0 (en) 1999-12-22 1999-12-22 Novel compounds
PCT/GB2000/004856 WO2001046137A1 (en) 1999-12-22 2000-12-18 Farnesyl transferase inhibitors

Publications (1)

Publication Number Publication Date
BR0016669A true BR0016669A (pt) 2002-10-08

Family

ID=10866834

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0016669-3A BR0016669A (pt) 1999-12-22 2000-12-18 Composto, e, composição farmacêutica

Country Status (27)

Country Link
US (1) US7101897B2 (pt)
EP (1) EP1255733B1 (pt)
JP (1) JP3742593B2 (pt)
KR (1) KR20020063251A (pt)
CN (2) CN1680313A (pt)
AR (1) AR029460A1 (pt)
AT (1) ATE316074T1 (pt)
AU (1) AU776003B2 (pt)
BR (1) BR0016669A (pt)
CA (1) CA2387579A1 (pt)
CO (1) CO5360641A1 (pt)
CZ (1) CZ20022125A3 (pt)
DE (1) DE60025650D1 (pt)
EE (1) EE200200206A (pt)
GB (1) GB9930318D0 (pt)
HU (1) HUP0204135A3 (pt)
IL (1) IL149871A0 (pt)
IS (1) IS6358A (pt)
MX (1) MXPA02005981A (pt)
MY (1) MY133606A (pt)
NO (1) NO20022924L (pt)
NZ (1) NZ518341A (pt)
PL (1) PL355887A1 (pt)
RU (1) RU2259997C2 (pt)
SK (1) SK8642002A3 (pt)
WO (1) WO2001046137A1 (pt)
ZA (1) ZA200202694B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005117864A1 (en) * 2004-05-28 2005-12-15 Astrazeneca Ab Combination product comprising anastrozole and a dual prenyl transferase inhibitor
JP4880473B2 (ja) * 2004-10-08 2012-02-22 壽製薬株式会社 ホスホン酸誘導体及び血中の高リン酸が関与する疾患の治療剤
WO2007092285A2 (en) * 2006-02-02 2007-08-16 Link Medicine Corporation Treatment of synucleinopathies
US8232402B2 (en) 2008-03-12 2012-07-31 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
WO2010057006A1 (en) 2008-11-13 2010-05-20 Link Medicine Corporation Azaquinolinone derivatives and uses thereof
US8975247B2 (en) 2009-03-18 2015-03-10 The Board Of Trustees Of The Leland Stanford Junion University Methods and compositions of treating a flaviviridae family viral infection
WO2011088126A2 (en) * 2010-01-13 2011-07-21 Eiger Biopharmaceuticals, Inc. Treatment of viral infection with prenyltransferase inhibitors

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1283906C (en) 1983-05-09 1991-05-07 Makoto Sunagawa .beta.-LACTAM COMPOUNDS AND PRODUCTION THEREOF
JPS60233076A (ja) 1984-05-03 1985-11-19 Sumitomo Chem Co Ltd 新規なβ−ラクタム化合物およびその製造法
EP0182213B1 (en) 1984-11-08 1990-09-26 Sumitomo Pharmaceuticals Company, Limited Carbapenem compounds and production thereof
KR880006244A (ko) 1986-11-24 1988-07-22 후지사와 도모 기찌 로 3-피롤리디닐티오-1-아자바이스클로[3.2.0]햅트2-엔-2-카르복실산 화합물 및 이의 제조방법
GB8921635D0 (en) 1989-09-25 1989-11-08 Fujisawa Pharmaceutical Co 3-pyrrolidinylthio-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid derivatives
CA2036163C (en) 1990-02-14 2001-06-19 Makoto Sunagawa Novel beta-lactam compounds and their production
NZ237191A (en) 1990-02-23 1992-12-23 Sankyo Co 2-((substituted amide) substituted heterocyclylthio) carbpen-2-em derivatives and pharmaceutical compositions
GB9107363D0 (en) 1991-04-08 1991-05-22 Ici Plc Antibiotic compounds
US6083917A (en) 1990-04-18 2000-07-04 Board Of Regents, The University Of Texas System Methods and compositions for the identification, characterization and inhibition of farnesyltransferase
US5185248A (en) * 1990-05-08 1993-02-09 E. R. Squibb & Sons, Inc. Farnesyl-protein transferase assay for identifying compounds that block neoplastic transformation
JPH0578360A (ja) 1991-01-31 1993-03-30 Banyu Pharmaceut Co Ltd ２−［２−（スルフアモイルアルキル）ピロリジニルチオカルバペネム誘導体
GB9107342D0 (en) 1991-04-08 1991-05-22 Ici Plc Antibiotic compounds
GB9107341D0 (en) 1991-04-08 1991-05-22 Ici Plc Antibiotic compounds
CA2070305A1 (en) 1991-06-04 1992-12-05 Isao Kawamoto 1-methylcarbapenem derivatives, their preparation and their use as antibiotics
JPH04368386A (ja) 1991-06-18 1992-12-21 Sankyo Co Ltd １−メチルカルバペネム−３−カルボン酸の製造法
US5360798A (en) 1991-07-04 1994-11-01 Shionogi Seiyaku Kabushiki Kaisha Aminooxypyrrolidinylthiocarbapenem compounds
ATE126059T1 (de) 1991-10-11 1995-08-15 Squibb & Sons Inc Verwendung von farnesyl-protein transferaseinhibitoren zur herstellung eines arzneimittels zur blockierung von durch ras- oncogenen hervorgerufenen neoplastischen transformationen von zellen.
JPH05239058A (ja) 1991-12-17 1993-09-17 Fujisawa Pharmaceut Co Ltd ３−ピロリジニルチオ−１−アザビシクロ［３．２．０ヘプト−２−エン−２−カルボン酸化合物
GB9202298D0 (en) * 1992-02-04 1992-03-18 Ici Plc Antibiotic compounds
CZ290002B6 (cs) 1992-03-11 2002-05-15 Sankyo Company Limited Antimikrobiální karbapenemové deriváty, způsob výroby a farmaceutický prostředek
GB9304156D0 (en) 1992-03-26 1993-04-21 Zeneca Ltd Antibiotic compounds
CA2091309A1 (en) 1992-03-26 1993-09-27 Frederic H. Jung Antibiotic compounds
EP0636133A1 (en) 1992-04-13 1995-02-01 Fujisawa Pharmaceutical Co., Ltd. Substituted 3-pyrrolidinylthio-carbapenems as antimicrobial agents
EP0581501B1 (en) 1992-07-21 1998-09-09 Zeneca Limited Antibiotic carbapenem compounds
EP0581502B1 (en) 1992-07-21 1998-10-21 Zeneca Limited Antibiotic carbapenem compounds
CA2099818A1 (en) 1992-07-21 1994-01-22 Frederic H. Jung Antibiotic compounds
EP0590885B1 (en) 1992-09-28 2000-03-15 Zeneca Limited Antibiotic carbapenem compounds
CA2106330A1 (en) 1992-10-07 1994-04-08 Patrice J. Siret Antibiotic compounds
CA2118985A1 (en) 1993-04-02 1994-10-03 Dinesh V. Patel Heterocyclic inhibitors of farnesyl protein transferase
CA2165176A1 (en) 1993-06-18 1995-01-05 Samuel L. Graham Inhibitors of farnesyl-protein transferase
JP2534823B2 (ja) 1993-07-07 1996-09-18 日本電気株式会社 印刷装置
US5468733A (en) 1993-09-30 1995-11-21 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5576293A (en) 1993-09-30 1996-11-19 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
CA2155448A1 (en) 1994-08-11 1996-02-12 Katerina Leftheris Inhibitors of farnesyl protein transferase
US5571835A (en) 1994-09-29 1996-11-05 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU706008B2 (en) 1995-03-29 1999-06-03 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
CN1064682C (zh) 1995-07-31 2001-04-18 盐野义制药株式会社 具有磷脂酶a2抑制活性的吡咯烷衍生物
GB9515975D0 (en) * 1995-08-04 1995-10-04 Zeneca Ltd Chemical compounds
JPH1050029A (ja) 1996-05-28 1998-02-20 Nobuyuki Higuchi 情報記憶装置
JP2001500118A (ja) * 1996-08-17 2001-01-09 ゼネカ・リミテッド ファルネシルタンパク質トランスフェラーゼ阻害剤としての３―メルカプトピロリジン
JP2001509156A (ja) * 1997-01-29 2001-07-10 ゼネカ・リミテッド ファルネシルプロテイントランスフェラーゼの阻害剤
JP2002518985A (ja) 1997-05-07 2002-06-25 ユニバーシティー・オブ・ピッツバーグ タンパク質イソプレニルトランスフェラーゼの阻害剤
JP2002503650A (ja) 1998-02-10 2002-02-05 アストラゼネカ ユーケー リミテッド ファルネシルトランスフェラーゼ阻害剤

Also Published As

Publication number Publication date
EP1255733B1 (en) 2006-01-18
CN1411442A (zh) 2003-04-16
NZ518341A (en) 2004-01-30
RU2002119405A (ru) 2004-01-10
ZA200202694B (en) 2003-12-31
CA2387579A1 (en) 2001-06-28
AU2201301A (en) 2001-07-03
IL149871A0 (en) 2002-11-10
DE60025650D1 (de) 2006-04-06
WO2001046137A1 (en) 2001-06-28
IS6358A (is) 2002-04-23
ATE316074T1 (de) 2006-02-15
AU776003B2 (en) 2004-08-19
US20030083348A1 (en) 2003-05-01
MY133606A (en) 2007-11-30
NO20022924D0 (no) 2002-06-18
GB9930318D0 (en) 2000-02-09
KR20020063251A (ko) 2002-08-01
SK8642002A3 (en) 2002-12-03
HUP0204135A2 (hu) 2003-03-28
AR029460A1 (es) 2003-07-02
PL355887A1 (en) 2004-05-31
EP1255733A1 (en) 2002-11-13
CN1680313A (zh) 2005-10-12
CN1229344C (zh) 2005-11-30
MXPA02005981A (es) 2005-07-01
US7101897B2 (en) 2006-09-05
CZ20022125A3 (cs) 2002-09-11
EE200200206A (et) 2003-04-15
NO20022924L (no) 2002-06-18
JP2003518091A (ja) 2003-06-03
CO5360641A1 (es) 2004-01-30
HUP0204135A3 (en) 2005-03-29
RU2259997C2 (ru) 2005-09-10
JP3742593B2 (ja) 2006-02-08

Similar Documents

Publication Publication Date Title
ES2130452T3 (es) Derivados de ciclobutano utilizados como inhibidores de la escualeno-sintetasa y de la farnesiltransferasa proteica.
MXPA03004832A (es) Compuestos y sus usos.
DE69905476D1 (en) Phosphonsaürederivate als ptp-1b-inhibitoren
ES2171723T3 (es) 3,4-diaril-2-hidroxi-2,5-dihidrofuranos como profarmacos de inhibidores de cox-2.
EA200501805A1 (ru) Фармацевтическая композиция, содержащая ингибитор фермента дипептидилпептидазы
IL162214A0 (en) Pyridine derivatives and pharmaceutical compositions containing the same
BR0209129A (pt) Compostos, composições farmacêuticas, métodos para tratamento de dores, métodos para modulação de uma resposta farmacológica e usos de compostos
MY148479A (en) Piperidinyl-substituted isoquinolone derivatives
LU91145I9 (pt)
MY146644A (en) Cyclohexylamin isoquinolone derivatives
PT1246809E (pt) Compostos de 5-aril-1h-1,2,4-triazole como inibidores de ciclooxigenase-2 e composicoes farmaceuticas que os contem
GB2340751B (en) Pharmaceutical compositions
BR0209128A (pt) Compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
WO2001042243A3 (en) Protein kinase inhibitors
BR0016669A (pt) Composto, e, composição farmacêutica
FR2813308B1 (fr) Aminoalkoxybenzoyl-benzofurannes ou benzothiophenes, leur procede de preparation ainsi que les compositions les contenant
ES2147973T3 (es) Estirenos alquilatados como profarmacos de inhibidores de cox-2.
MXPA02000330A (es) Pirrolidinas y piperidinas neurotroficas y composiciones y metodos relacionados.
ES2182035T3 (es) Derivados del bisarilciclobuteno como inhibidores de ciclooxigenasa.
NZ326283A (en) Diphenyl stilbenes as prodrugs to cox-2 inhibitors
BR0016667A (pt) Composto, e, composição farmacêutica
BR0014759A (pt) Inibidores de metaloprotease beta dissubstituìdos
WO2000039716A3 (en) Arylpropenylimidazoles as farnesyl-protein transferase inhibitors
ES2183346T3 (es) Sistemas conjugados de bis-fosfonato con restos alquilantes que tienen actividad antitumoral.
WO2000037465A3 (en) Novel derivatives of swainsonine, processes for their preparation, and their use as therapeutic agents

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2008 DE 30/06/2009.